$DMAC
DiaMedica Therapeutics Inc.

2024 Q4 Form 10-Q Financial Statement

#000143774924034925 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.900M
YoY Change 0.53%
% of Gross Profit
Research & Development $4.983M
YoY Change 52.29%
% of Gross Profit
Depreciation & Amortization $10.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $4.983M
YoY Change 52.29%
Operating Profit -$6.883M
YoY Change 33.47%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $616.0K
YoY Change -11.11%
Pretax Income -$6.267M
YoY Change 40.39%
Income Tax $7.000K
% Of Pretax Income
Net Earnings -$6.274M
YoY Change 40.33%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15
Diluted Earnings Per Share -$0.15
COMMON SHARES
Basic Shares Outstanding 42.76M 42.75M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.20M
YoY Change 8.02%
Cash & Equivalents $4.134M
Short-Term Investments $46.06M
Other Short-Term Assets $280.0K
YoY Change -75.0%
Inventory
Prepaid Expenses
Receivables $290.0K
Other Receivables $0.00
Total Short-Term Assets $50.77M
YoY Change 6.02%
LONG-TERM ASSETS
Property, Plant & Equipment $151.0K
YoY Change 11.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.308M
YoY Change
Total Long-Term Assets $1.757M
YoY Change -82.86%
TOTAL ASSETS
Total Short-Term Assets $50.77M
Total Long-Term Assets $1.757M
Total Assets $52.52M
YoY Change -9.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.171M
YoY Change 35.69%
Accrued Expenses $3.024M
YoY Change 146.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $14.00K
YoY Change
Total Short-Term Liabilities $4.297M
YoY Change 98.02%
LONG-TERM LIABILITIES
Long-Term Debt $249.0K
YoY Change
Other Long-Term Liabilities $14.00K
YoY Change -95.88%
Total Long-Term Liabilities $263.0K
YoY Change -22.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.297M
Total Long-Term Liabilities $263.0K
Total Liabilities $4.560M
YoY Change 81.67%
SHAREHOLDERS EQUITY
Retained Earnings -$132.1M
YoY Change 19.66%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.00M
YoY Change
Total Liabilities & Shareholders Equity $52.52M
YoY Change -9.66%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$6.274M
YoY Change 40.33%
Depreciation, Depletion And Amortization $10.00K
YoY Change 0.0%
Cash From Operating Activities -$4.470M
YoY Change -6.88%
INVESTING ACTIVITIES
Capital Expenditures $9.000K
YoY Change -10.0%
Acquisitions
YoY Change
Other Investing Activities -$5.576M
YoY Change -560.83%
Cash From Investing Activities -$5.585M
YoY Change -565.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 123.0K
YoY Change -1330.0%
NET CHANGE
Cash From Operating Activities -4.470M
Cash From Investing Activities -5.585M
Cash From Financing Activities 123.0K
Net Change In Cash -9.932M
YoY Change 175.12%
FREE CASH FLOW
Cash From Operating Activities -$4.470M
Capital Expenditures $9.000K
Free Cash Flow -$4.479M
YoY Change -6.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4983000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3272000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1900000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1885000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18262000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1220000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14199000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4543000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
280000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
354000 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
485000 usd
CY2023Q4 us-gaap Assets
Assets
54160000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
926000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1777000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
80000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2786000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
316000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
317000 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37958000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4477000 usd
dei Entity File Number
EntityFileNumber
001-36291
dei Entity Registrant Name
EntityRegistrantName
DIAMEDICA THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Address Line1
EntityAddressAddressLine1
301 Carlson Parkway, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55305
dei City Area Code
CityAreaCode
763
dei Local Phone Number
LocalPhoneNumber
496-5454
dei Security12b Title
Security12bTitle
Voting common shares, no par value per share
dei Trading Symbol
TradingSymbol
DMAC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4471000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16544000 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
0 usd
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
48352000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
53675000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
298000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151000 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
1757000 usd
CY2024Q3 us-gaap Assets
Assets
52524000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1171000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3024000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4297000 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
263000 usd
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42766497
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42766497
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37958000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
179985000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
81000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132102000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
47964000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52524000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
14000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
166609000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115558000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
51057000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54160000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9433000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5675000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5986000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5157000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-15419000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1739000 usd
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4134000 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
46063000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
369000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
50767000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
88000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
249000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12587000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
616000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
693000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-53000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14273000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30751329
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
us-gaap Net Income Loss
NetIncomeLoss
-14220000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
132000 usd
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42760582
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1308000 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
0 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
131000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6883000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6267000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16523000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6274000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-64000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
75000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6142000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4535000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16469000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42751577
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37949422
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39604179
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
51057000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
488000 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-45000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5151000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
46349000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
100000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11747000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 usd
CY2024Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
443000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5119000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
53415000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001401040
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
dei Document Type
DocumentType
10-Q
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
290000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
411000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
14000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4464000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
126000 usd
CY2024Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
565000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
132000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6274000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
47964000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31827000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
422000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
45000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5272000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
27022000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1400000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36852000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
380000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-34000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
59743000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
425000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-64000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4471000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
55629000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16544000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14220000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1496000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1227000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1013000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
856000 usd
dmac Noncash Lease Expense
NoncashLeaseExpense
56000 usd
dmac Noncash Lease Expense
NoncashLeaseExpense
52000 usd
us-gaap Depreciation
Depreciation
28000 usd
us-gaap Depreciation
Depreciation
22000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-79000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
228000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-131000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
860000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
1308000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
245000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
129000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1188000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-182000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15642000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14916000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39623000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
64537000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
43000000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
40135000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3359000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24423000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11747000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
36848000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
133000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11874000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36843000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-409000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2496000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4543000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4728000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4134000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2232000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
30000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
20000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
26000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132100000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16500000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15600000 usd
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
50200000 usd
CY2024Q3 dmac Working Capital
WorkingCapital
46500000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
48000000 usd
CY2024Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
288000 usd
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
298000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
254000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
231000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
103000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
131000 usd
CY2024Q3 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
1297000 usd
CY2023Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
258000 usd
CY2024Q3 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
896000 usd
CY2023Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
632000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
730000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
766000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
91000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
98000 usd
CY2024Q3 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
10000 usd
CY2023Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
23000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3024000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1777000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
78000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
78000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
64000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
66000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
28000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
113000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
116000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
119000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
10000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
386000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
49000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
337000 usd
dmac Stock Issued During Period Shares Restricted Stock Units
StockIssuedDuringPeriodSharesRestrictedStockUnits
17747
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
70750
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
133000 usd
dmac Stock Issued During Period Shares Settlement Of Deferred Stock Units
StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits
17621
dmac Stock Issued During Period Shares Restricted Stock Units
StockIssuedDuringPeriodSharesRestrictedStockUnits
12867
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8286136
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6274000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4471000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16544000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14220000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42751577
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37949422
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39604179
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30751329
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
565000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
425000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1496000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1227000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
70750
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.88
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4632438
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.31
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4875000 usd
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
4632438
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2024Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.31
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2174353
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P5Y7M6D

Files In Submission

Name View Source Status
0001437749-24-034925-index-headers.html Edgar Link pending
0001437749-24-034925-index.html Edgar Link pending
0001437749-24-034925.txt Edgar Link pending
0001437749-24-034925-xbrl.zip Edgar Link pending
dmac-20240930.xsd Edgar Link pending
dmtp20240930_10q.htm Edgar Link pending
ex_743362.htm Edgar Link pending
ex_743363.htm Edgar Link pending
ex_743364.htm Edgar Link pending
ex_743365.htm Edgar Link pending
ex_743381.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image01.jpg Edgar Link pending
image1.jpg Edgar Link pending
image2.jpg Edgar Link pending
image3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
dmac-20240930_cal.xml Edgar Link unprocessable
dmac-20240930_def.xml Edgar Link unprocessable
dmac-20240930_lab.xml Edgar Link unprocessable
dmac-20240930_pre.xml Edgar Link unprocessable
dmtp20240930_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending